

**IN THE CLAIMS**

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-9 (canceled)

10. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising treating Clopidogrel base with dilute H<sub>2</sub>SO<sub>4</sub> in one or more suitable solvent(s) and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).
11. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising treating Clopidogrel base with concentrated H<sub>2</sub>SO<sub>4</sub> in one or more suitable solvent(s) and water and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).
12. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising dissolving/contacting Clopidogrel bisulfate in any form including crystalline forms II, III, IV, V, VI or any other crystalline forms or amorphous form or in the form of oil with one or more suitable solvent(s) and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).
13. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising treating Clopidogrel bisulfate in any form including crystalline forms II, III, IV, V, VI or any other crystalline forms or amorphous form or in the form of oil is dissolved or contacted with one or more suitable solvent(s) and water and subsequently isolating the crystalline form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

14. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising

- i. treating (S)-(+)-Clopidogrel camphor-sulfonate in a mixture of a suitable solvent(s) and water with a suitable-base(s), to obtain Clopidogrel base wherein the ~~said~~ suitable solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and [or] mixtures thereof[.,.];
- ii. treating the Clopidogrel base with dil. H<sub>2</sub>SO<sub>4</sub> in a suitable-solvent(s)[.,.]; and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

15. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising

- i. treating (S)-(+)-Clopidogrel camphor-sulfonate in a mixture of a suitable solvent(s) and water with a suitable-base, to obtain Clopidogrel base wherein the ~~suitable~~ solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and [or] mixtures thereof;
- ii. treating the Clopidogrel base with concentrated H<sub>2</sub>SO<sub>4</sub> in a mixture of suitable solvent(s) and water; and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

16. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising

- i. treating Clopidogrel base with dil. H<sub>2</sub>SO<sub>4</sub> in suitable-solvent(s),
- ii. seeding with crystals of form-I, and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

17. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising

- i. treating Clopidogrel base with concentrated  $H_2SO_4$  in ~~suitable~~ solvent(s) and water;
- ii. seeding with crystals of form-I; and
- iii. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

18. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising

- i. treating Clopidogrel camphor-sulfonate in a ~~suitable~~ solvent(s) with a suitable base, to obtain Clopidogrel base wherein the ~~said~~ ~~suitable~~ solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and [[or]] mixtures thereof;
- ii. treating the Clopidogrel base with dil.  $H_2SO_4$  in a ~~suitable~~ solvent(s);
- iii. seeding with crystals of form-I; and
- iv. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

19. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, comprising

- i. treating Clopidogrel camphor-sulfonate in one or more ~~suitable~~ solvent(s) with a suitable base, to obtain Clopidogrel base wherein the ~~suitable~~ solvent is selected from the group consisting of ethyl acetate, dichloromethane, dichloroethane, chloroform, and [[or]] mixtures thereof;
- ii. treating the Clopidogrel base with concentrated  $H_2SO_4$  in a mixture of ~~suitable~~ solvent(s) and water;
- iii. seeding with crystals of form-I; and
- iv. separating the crystals of form I of (S)-(+)-Clopidogrel bisulfate, which has a melting point of 184 ± 3°C, from the solvent(s).

20. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 10, wherein the ~~said suitable~~ solvent is selected from the group consisting of C<sub>6</sub>-C<sub>12</sub> alcohols which may be linear or branched, primary, secondary or tertiary alcohols such as hexanol, 2-hexanol, 3-hexanol, isohexanol, heptanol, 2-heptanol, 3-heptanol, 4-heptanol, octanol, iso-octanol, decanol or mixtures thereof.

21. (currently amended) A process for the preparation of form I of (S)-(+)-Clopidogrel bisulfate claimed in claim 10, wherein the ~~suitable~~-base is selected from the group consisting of NaOH, KOH, LiOH, NaHCO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub>, and K<sub>2</sub>CO<sub>3</sub>.

Claims 22-24 (canceled)